1 Department of Physical Medicine and Rehabilitation, Indiana University School of Medicine , Indianapolis, Indiana.
2 Rehabilitation Hospital of Indiana , Indianapolis, Indiana.
J Neurotrauma. 2018 Oct 1;35(19):2298-2305. doi: 10.1089/neu.2018.5767. Epub 2018 Jun 7.
Despite limited evidence to support the use of amantadine to enhance cognitive function after traumatic brain injury (TBI), the clinical use for this purpose is highly prevalent and is often based on inferred belief systems. The aim of this study was to assess effect of amantadine on cognition among individuals with a history of TBI and behavioral disturbance using a parallel-group, randomized, double-blind, placebo-controlled trial of amantadine 100 mg twice-daily versus placebo for 60 days. Included in the study were 119 individuals with two or more neuropsychological measures greater than 1 standard deviation below normative means from a larger study of 168 individuals with chronic TBI (>6 months post-injury) and irritability. Cognitive function was measured at treatment days 0, 28, and 60 with a battery of neuropsychological tests. Composite indices were generated: General Cognitive Index (included all measures), a Learning Memory Index (learning/memory measures), and Attention/Processing Speed Index (attention and executive function measures). Repeated-measures analysis of variance revealed statistically significant between-group differences favoring the placebo group at day 28 for General Cognitive Index (p = 0.002) and Learning Memory Index (p = 0.001), but not Attention/Processing Speed Index (p = 0.25), whereas no statistically significant between-group differences were found at day 60. There were no statistically significant between-group differences on adverse events. Cognitive function in individuals with chronic TBI is not improved by amantadine 100 mg twice-daily. In the first 28 days of use, amantadine may impede cognitive processing. However, the effect size was small and mean scores for both groups were generally within expectations for persons with history of complicated mild-to-severe TBI, suggesting that changes observed across assessments may not have functional significance. The use of amantadine to enhance cognitive function is not supported by these findings.
尽管有限的证据支持使用金刚烷胺来增强创伤性脑损伤(TBI)后的认知功能,但出于这种目的的临床应用非常普遍,而且通常基于推断的信仰体系。本研究旨在评估金刚烷胺对 119 名 TBI 后伴有行为障碍的个体认知的影响,采用平行组、随机、双盲、安慰剂对照试验,比较每日两次 100mg 金刚烷胺与安慰剂治疗 60 天。该研究纳入了 168 名慢性 TBI(>6 个月后损伤)和易激惹患者的更大研究中,2 项或 2 项以上神经心理学测量结果大于正常值 1 个标准差的个体。在治疗第 0、28 和 60 天,使用一系列神经心理学测试测量认知功能。生成综合指数:一般认知指数(包括所有测量指标)、学习记忆指数(学习/记忆测量指标)和注意/处理速度指数(注意和执行功能测量指标)。重复测量方差分析显示,在第 28 天,金刚烷胺组在一般认知指数(p=0.002)和学习记忆指数(p=0.001)方面优于安慰剂组,而在注意/处理速度指数(p=0.25)方面无统计学差异,而在第 60 天未发现组间统计学差异。两组不良事件无统计学差异。100mg 金刚烷胺每日两次不能改善慢性 TBI 患者的认知功能。在使用的前 28 天,金刚烷胺可能会阻碍认知处理。然而,效应大小较小,且两组的平均分数通常都在预期范围内,即有复杂轻度至重度 TBI 病史的患者,表明评估过程中的变化可能没有功能意义。这些发现不支持使用金刚烷胺来增强认知功能。